Alvotech reports 2025 revenue growth and plans FDA resubmission for Reykjavik facility

finance.yahoo.com

Alvotech expects to resubmit applications to the FDA in the second quarter of 2026 after addressing regulatory observations from a July 2025 inspection. The company has implemented a comprehensive quality improvement program at its Reykjavik manufacturing facility and is confident in resolving the issues. Alvotech is also advancing plans for a second manufacturing source in the United States for key products. In 2025, Alvotech reported a 21% increase in total revenues to $593 million and a 27% rise in adjusted EBITDA to $137 million.


With a significance score of 1.3, this news ranks in the top 45% of today's 33931 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Alvotech reports 2025 revenue growth and plans FDA resubmission for Reykjavik facility | News Minimalist